Balchem Corp Dossier - Source-backed chat

Balchem Corp

BCPCNASDAQ

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)0.87

Intrinsic Value $174.50median of 6 methods · middle span $151-$205based on filings through 30 Jun 2026

Market Price $164.96Price as of 30 Sep 2026

Near fair valueIntrinsic value is 6% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $5.3B

Enterprise Value $5.4B

Shares Outstanding 32.1M diluted

Moat Rating Narrow

Next Earnings Date29 Oct 2026

Last ex-dividend23 Dec 2025

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Balchem Corporation (NASDAQ: BCPC) is a high-quality specialty ingredients leader positioned at the intersection of human nutrition, animal health, and specialty medical sterilization. The company exhibits robust financial health, characterized by consistent organic growth, high EBITDA margins, and exceptional cash flow generation. Balchem's defensive business model, supported by secular 'better-for-you' health trends and strong pricing power, allows it to navigate macroeconomic volatility effectively. Furthermore, the company has demonstrated outstanding progress on its ESG initiatives, already exceeding its 2030 greenhouse gas emissions reduction target. While trading at a premium valuation, Balchem's strong balance sheet, low leverage, and consistent double-digit dividend growth make it an attractive long-term investment.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$165.00

Mean target$209.25

High · most bullish analyst$242.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$165.00

Severe raw material cost inflation, persistent supply chain bottlenecks, or restrictive EPA regulations on ethylene oxide compress margins. Slower-than-expected adoption of premium nutritional ingredients in a weak consumer environment limits organic growth, leading to a multiple contraction.

Base CaseCentral scenario

$209.25

Matches the consensus mean

Balchem continues its steady growth trajectory, delivering high-single-digit revenue growth driven by solid performance across all three segments. Margins remain stable as pricing actions offset modest raw material inflation. The company maintains its strong cash conversion, supporting organic reinvestment, strategic bolt-on acquisitions, and ongoing dividend increases.

Bull CaseUpside scenario

$242.00

Accelerating demand for choline and chelated minerals in human nutrition, combined with rapid international expansion and successful high-margin M&A, drives double-digit top-line growth. Operating leverage and favorable product mix expand adjusted EBITDA margins toward 30%, leading to significant earnings outperformance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Resilient business model with leading market positions in highly attractive, defensive nutrition and health niches.
Strong financial profile characterized by high margins, low capital intensity, and exceptional free cash flow conversion.
Excellent ESG track record, including a 31% absolute reduction in Scope 1 and Scope 2 emissions, surpassing the 2030 target ahead of schedule.
Consistent capital allocation strategy with a 17-year history of double-digit dividend increases and active share repurchases.

Key Investment Risks

Exposure to raw material cost volatility and potential supply chain disruptions.
Strict environmental and safety regulations, particularly regarding ethylene oxide and propylene oxide sterilization technologies.
High valuation multiples relative to near-term growth, which could expose the stock to volatility during market pullbacks.

Thesis Invalidation Triggers

A sustained decline in organic revenue growth below mid-single digits.
Significant gross margin compression below 33% due to unmitigated cost inflation.
Severe regulatory restrictions or bans on key sterilization chemicals that disrupt the Specialty Products segment.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.